WO2021043389A1 - Composition de ginseng et son utilisation en tant que médicament pour le traitement ou la prévention d'une déficience cognitive - Google Patents

Composition de ginseng et son utilisation en tant que médicament pour le traitement ou la prévention d'une déficience cognitive Download PDF

Info

Publication number
WO2021043389A1
WO2021043389A1 PCT/EP2019/073494 EP2019073494W WO2021043389A1 WO 2021043389 A1 WO2021043389 A1 WO 2021043389A1 EP 2019073494 W EP2019073494 W EP 2019073494W WO 2021043389 A1 WO2021043389 A1 WO 2021043389A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
ginsan
gintonin
ginsenoside
subject
Prior art date
Application number
PCT/EP2019/073494
Other languages
English (en)
Inventor
Pierre-Antoine Mariage
Paul-Evence COPPEE
Original Assignee
Botalys Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Botalys Sa filed Critical Botalys Sa
Priority to PCT/EP2019/073494 priority Critical patent/WO2021043389A1/fr
Priority to EP20771997.2A priority patent/EP4025231A1/fr
Priority to AU2020342706A priority patent/AU2020342706A1/en
Priority to JP2022513665A priority patent/JP2022553120A/ja
Priority to US17/753,391 priority patent/US20220288147A1/en
Priority to PCT/EP2020/074649 priority patent/WO2021043927A1/fr
Publication of WO2021043389A1 publication Critical patent/WO2021043389A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition, son kit et sa préparation pour améliorer les performances cognitives chez un sujet. L'invention concerne également la composition destinée à être utilisée en tant que substance médicale ou thérapeutique. La composition comprend un ginsénoside rare, un ginsan et une gintonine. De préférence, le rapport de ginsan à gintonine est supérieur à 500 : 1 et inférieur à 1 : 100. De préférence, le rapport des ginsénosides rares à ginsan et gintonine est supérieur à 250 : 1 et inférieur à 1 : 40.
PCT/EP2019/073494 2019-09-03 2019-09-03 Composition de ginseng et son utilisation en tant que médicament pour le traitement ou la prévention d'une déficience cognitive WO2021043389A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
PCT/EP2019/073494 WO2021043389A1 (fr) 2019-09-03 2019-09-03 Composition de ginseng et son utilisation en tant que médicament pour le traitement ou la prévention d'une déficience cognitive
EP20771997.2A EP4025231A1 (fr) 2019-09-03 2020-09-03 Composition de ginseng et son utilisation en tant que médicament
AU2020342706A AU2020342706A1 (en) 2019-09-03 2020-09-03 Ginseng composition and use thereof as a medicament
JP2022513665A JP2022553120A (ja) 2019-09-03 2020-09-03 ニンジン組成物及び医薬としてのその使用
US17/753,391 US20220288147A1 (en) 2019-09-03 2020-09-03 Ginseng composition and use thereof as a medicament
PCT/EP2020/074649 WO2021043927A1 (fr) 2019-09-03 2020-09-03 Composition de ginseng et son utilisation en tant que médicament

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2019/073494 WO2021043389A1 (fr) 2019-09-03 2019-09-03 Composition de ginseng et son utilisation en tant que médicament pour le traitement ou la prévention d'une déficience cognitive

Publications (1)

Publication Number Publication Date
WO2021043389A1 true WO2021043389A1 (fr) 2021-03-11

Family

ID=67988954

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2019/073494 WO2021043389A1 (fr) 2019-09-03 2019-09-03 Composition de ginseng et son utilisation en tant que médicament pour le traitement ou la prévention d'une déficience cognitive

Country Status (1)

Country Link
WO (1) WO2021043389A1 (fr)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4157894A (en) 1976-06-03 1979-06-12 Inverni Della Beffa S.P.A. Production and analysis of ginseng root extract
US5137878A (en) 1989-01-13 1992-08-11 Pang Peter K T Composition and method for treatment of senile dementia
US5230889A (en) 1991-04-12 1993-07-27 Iwatani Sangyo Kabushiki Kaisha Enriched nutritious food product comprising powder of ginseng and method for producing powder of ginseng
US6083932A (en) 1997-04-18 2000-07-04 Cv Technologies Inc. Pharmaceutical compositions derived from ginseng and methods of treatment using same
US6156291A (en) 1997-08-28 2000-12-05 Cv Technologies Inc. Chemical and pharmacological standardization of herbal extracts
WO2005120536A1 (fr) * 2004-06-11 2005-12-22 Unigen, Inc. Composition a base de ginseng destinee a la prevention ou a l'attenuation de la baisse de la faculte de concentration et de la memoire
US7235267B1 (en) 1999-08-30 2007-06-26 Japan Science And Technology Corporation Brain cell or nerve cell-protecting agents comprising medicinal ginseng
EP2502933A2 (fr) 2009-11-17 2012-09-26 Konkuk University Industrial Cooperation Corp. Procédé de préparation de la gintonine, qui est une nouvelle glycolipoprotéine issue de panax ginseng, et gintonine, qui est une nouvelle glycolipoprotéine, préparée par le procédé
WO2018148821A1 (fr) 2017-02-16 2018-08-23 Neurodyn Life Sciences Inc. Composition et procédé pour améliorer la fonction cognitive et la biodisponibilité cérébrale de ginseng et de ginsénosides et pour traiter une maladie neurodégénérative et des troubles neurologiques

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4157894A (en) 1976-06-03 1979-06-12 Inverni Della Beffa S.P.A. Production and analysis of ginseng root extract
US5137878A (en) 1989-01-13 1992-08-11 Pang Peter K T Composition and method for treatment of senile dementia
US5230889A (en) 1991-04-12 1993-07-27 Iwatani Sangyo Kabushiki Kaisha Enriched nutritious food product comprising powder of ginseng and method for producing powder of ginseng
US6083932A (en) 1997-04-18 2000-07-04 Cv Technologies Inc. Pharmaceutical compositions derived from ginseng and methods of treatment using same
US6156291A (en) 1997-08-28 2000-12-05 Cv Technologies Inc. Chemical and pharmacological standardization of herbal extracts
US7235267B1 (en) 1999-08-30 2007-06-26 Japan Science And Technology Corporation Brain cell or nerve cell-protecting agents comprising medicinal ginseng
WO2005120536A1 (fr) * 2004-06-11 2005-12-22 Unigen, Inc. Composition a base de ginseng destinee a la prevention ou a l'attenuation de la baisse de la faculte de concentration et de la memoire
EP2502933A2 (fr) 2009-11-17 2012-09-26 Konkuk University Industrial Cooperation Corp. Procédé de préparation de la gintonine, qui est une nouvelle glycolipoprotéine issue de panax ginseng, et gintonine, qui est une nouvelle glycolipoprotéine, préparée par le procédé
WO2018148821A1 (fr) 2017-02-16 2018-08-23 Neurodyn Life Sciences Inc. Composition et procédé pour améliorer la fonction cognitive et la biodisponibilité cérébrale de ginseng et de ginsénosides et pour traiter une maladie neurodégénérative et des troubles neurologiques

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
"Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems", 2004, LIPPINCOTT WILLIAMS & WILKINS
"Remington: Science and Practice of Pharmacy", 2005, LIPPINCOTT WILLIAMS & WILKINS
AMERICAN BOTANICAL COUNCIL: "BOTALYS Adopts Asian Ginseng through ABC's Adopt-an-Herb Program", 20 May 2019 (2019-05-20), XP055692150, Retrieved from the Internet <URL:https://www.globenewswire.com/news-release/2019/05/20/1829114/0/en/BOTALYS-Adopts-Asian-Ginseng-through-ABC-s-Adopt-an-Herb-Program.html> [retrieved on 20200506] *
ANONYMOUS: "Ginseng HRG80 in Stress and Fatigue - Full Text View - ClinicalTrials.gov", 13 May 2019 (2019-05-13), XP055692252, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/NCT03947554> [retrieved on 20200506] *
COURT: "Ginseng: The Genus Panax", 2000, HARWOOD ACADEMIC PUBLISHERS, article "The Principal Active Chemicals in Panax species"
HYE-SOOK CHOIKYUNG-HO KIMEUNWHA SOHNJONG-DAE PARKBYUNG-OH KIMEUN-YI MOONDONG-KWON RHEESUHKNEUNG PYO: "Red Ginseng Acidic Polysaccharide (RGAP) in Combination with IFN-Y Results in Enhanced Macrophage Function through Activation of the NF-KB Pathway", BIOSCI. BIOTECHNOL. BIOCHEM., vol. 72, no. 7, 2008, pages 1817 - 1825
IK-HYUN CHO: "Effects of Panax ginseng in Neurodegenerative Diseases", JOURNAL OF GINSENG RESEARCH, vol. 36, no. 4, 15 October 2012 (2012-10-15), KR, pages 342 - 353, XP055361085, ISSN: 1226-8453, DOI: 10.5142/jgr.2012.36.4.342 *
K. HOSTETTMANNA. MARSTON: "Chemistry and Pharmacology of Natural Products: Saponins", 1995, CAMBRIDGE UNIVERSITY PRESS
KAWASHIMA ET AL., J. MED. PHARMACOL. SOC. WAKAN-YAKU, vol. 3, 1986, pages 235 - 236
OURA ET AL., JOURNAL OF BIOCHEMISTRY (TOKYO, vol. 77, no. 5, 1975, pages 1057 - 65
PIERRE-ANTOINE MARIAGE ET AL: "Efficacy of Panax ginseng Meyer Herbal Preparation HRG80 in Preventing and Mitigating Stress-Induced Failure of Cognitive Functions in Healthy Subjects: A Pilot, Randomized, Double-Blind, Placebo-Controlled Crossover Trial", PHARMACEUTICALS, vol. 13, no. 4, 29 March 2020 (2020-03-29), CH, pages 57, XP055691690, ISSN: 1424-8247, DOI: 10.3390/ph13040057 *
PIERRE-ANTOINE MARIAGE: "Ginseng HRG80 : un nouvel ingrédient naturel à l'efficacité renforcée", 13 November 2018 (2018-11-13), XP055692164, Retrieved from the Internet <URL:https://www.mynaturalorigins.com/fr/blog/ginseng-hrg80-un-nouvel-ingredient-naturel-a-l-efficacite-renforcee> [retrieved on 20200506] *
PIERRE-ANTOINE MARIAGE: "Ginseng HRG80 : un nouvel ingrédient naturel à l'efficacité renforcée", 22 November 2018 (2018-11-22), XP055692168, Retrieved from the Internet <URL:https://www.mynaturalorigins.com/fr/blog/ginseng-hrg80-un-nouvel-ingredient-naturel-a-l-efficacite-renforcee> [retrieved on 20200506] *
PIERRE-ANTOINE MARIAGE: "Pourquoi opter pour le ginseng HRG80 dans vos produits nutraceutiques ?", 20 November 2018 (2018-11-20), XP055692170, Retrieved from the Internet <URL:https://www.mynaturalorigins.com/fr/blog/pourquoi-opter-pour-le-ginseng-hrg80-dans-vos-produits-nutraceutiques> [retrieved on 20200506] *
SHIBATA ET AL., ECONOMIC AND MEDICINAL PLANT RESEARCH, WORLD SCIENTIFIC, PHILADELPHIA, 1985, pages 217 - 284
SUN-HYE CHOISEOK-WON JUNGHYUN-SOOK KIMHYEON-JOONG KIMBYUNG-HWAN LEEJOON YONG KIMJUNG-HYUN KIMSUNG HEE HWANGHYEWON RHIMHYOUNG-CHUN : "A brief method for preparation of gintonin-enriched fraction from ginseng", J GINSENG RES., vol. 39, 2015, pages 398 - 405, XP053034692, doi:10.1016/j.jgr.2015.05.002
YU ET AL., CHEM. PHARM. BULL., vol. 55, no. 2, 2007, pages 231 - 235

Similar Documents

Publication Publication Date Title
CN102802636B (zh) 藏花素水解产物
US6440448B1 (en) Food supplement/herbal composition for health enhancement
JP6873517B2 (ja) 成年女性、高齢者及び亜健康状態の人々に適用できる健康保持製品組成物
CA2555235C (fr) Medicament phytotherapique contre l&#39;hepatite c
CN104623670A (zh) 一种含西红花素的组合物及其应用
JP2006512330A (ja) 竹からの抽出のトリテルペノイドサポゲニン化合物の製法と用途
JP2003192605A (ja) リパーゼ阻害剤
CA2282234A1 (fr) Methode de renforcement de l&#39;activite antitumorale de matieres premieres, composition contenant des matieres premieres dont l&#39;activite a ete renforcee, methode d&#39;evaluation de l&#39;efficacite antitumorale d&#39;un traitement utilisant des matieres premieres et methode d&#39;evaluation de l&#39;efficacite des matieres premieres
CN112690450A (zh) 解酒护肝的组合物及其制备方法和包含其的产品
JP4961715B2 (ja) 老臭改善用経口組成物
US20050202105A1 (en) Water soluble compositions derived from plant material and preparation thereof
CN106266515B (zh) 参苓草组合物、参苓草饮品及制备方法
Padmavathi Chronic disease management with nutraceuticals
US20220288147A1 (en) Ginseng composition and use thereof as a medicament
WO2021043389A1 (fr) Composition de ginseng et son utilisation en tant que médicament pour le traitement ou la prévention d&#39;une déficience cognitive
CN105963330B (zh) 神秘果制剂及其应用
KR102581166B1 (ko) 황칠추출물을 포함하는 여드름 개선용 화장료 조성물
US20010009903A1 (en) Augmentation method for antitumor activity of substance containing amygdalin, composition containing augmented amygdalin contained substance, method for assessing antitumor efficacy of treatment for amygdalin contained substance and method for assessing antitumor, substance containing amygdalin
BE1027552B1 (fr) Composition du ginseng et son utilisation comme medicament pour le traitement ou la prevention du stress
KR102234860B1 (ko) 싸리 추출물을 포함하는 근위축 예방 및 치료용 조성물
KR101985660B1 (ko) 누룩으로 발효시킨 복합생약추출물을 포함하는 여드름 개선용 화장료 조성물
CN101816708B (zh) 治疗风湿病的中药组合物及其制备方法
KR100447668B1 (ko) 불용성 생리활성물질을 함유한 분산성 조각 젤리타입입자혼입 기능성음료 제조방법
JP7361903B2 (ja) 芫花、威霊仙、及び天麻の複合生薬抽出物を含む神経変性疾患の予防または治療用組成物
Kim et al. Study of efficacy and safety of ginseng seed oil in heathy subjects who have mild liver dysfunction: a randomized, double blinded, placebo-controlled study

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19769719

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19769719

Country of ref document: EP

Kind code of ref document: A1